News Group
18.10.2018

BUSINESS WIN

FEB-rin, first reproductive microbiome modulator

Helvet Health is proud to collaborate with FERRING for the launch of FEB-rin®, a specially formulated intravaginal ovule that significantly increases Lactobacilli presence during ovarian stimulation, influencing the vaginal microbiome towards a healthier bacterial state. FERRING is leading the innovation in the reproductive microbiome and fertility. Helvet Health is contributing in the creation of all strategic, medical, and creative campaign elements.

HELVET-HEALTH

18.10.2018

BUSINESS WIN

FEB-rin, first reproductive microbiome modulator

Helvet Health is proud to collaborate with FERRING for the launch of FEB-rin®, a specially formulated intravaginal ovule that significantly…

HELVET-HEALTH

02.10.2018

Haemonetics

Haemonetics, Leader in Blood Management Solutions

Haemonetics, a global leader in blood management solutions, has assigned Helvet Health with the task of reshaping its Digital Sales…

HELVET-HEALTH

30.08.2018

EVENT

The role of digital in rare diseases

What is the role of digital in healthcare – but more precisely – in rare diseases? Our Global Digital Manager,…

HELVET-HEALTH

07.08.2018

OUR TEAM

Uli Straehler has joined Helvet Health as Global Account Coordinator

We are pleased to announce the arrival of Uli Straehler as our new Global Account Coordinator part of Helvet Health.…

HELVET-GROUP

26.07.2018

AGENCY INAUGURATION

Helvet Health grows and moves office

We invite you to take a look at our agency party that took place on the 20th of June in…

HELVET-GROUP

24.07.2018

FERRING

Helvet Health launched new men’s health treatment in Urology

FERRING Pharmaceuticals, a leader in men’s health, Urology and Endocrinology – amongst other therapeutic categories – selected Helvet Health to…

HELVET-HEALTH

  • PRÉCECENTE
  • 1 sur 2
  • Suivante